Monoclonal antibodies to taxanes that neutralize the biological activity of paclitaxel

Gary S. Bignami, Susan L. Mooberry

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Recently it has been proposed that drug-specific neutralizing antibodies may limit side-effects that occur during chemotherapy. These studies were undertaken to determine if monoclonal antibodies, 3C6 specific to paclitaxel and 8A10 specific to taxane diterpenes, are inhibitors of paclitaxel-induced inhibition of proliferation and cellular microtubule and nuclear changes. The results show that 3C6 and 8A10 each inhibit paclitaxel-induced cytotoxicity, microtubular bundling, stabilization from vinblastine-induced microtubule depolymerization and the formation of micronuclei. We conclude that these antibodies effectively neutralize paclitaxel activity in vitro and that they may be useful to determine if antibody-blocking strategies can prevent dose-limiting toxicities.

Original languageEnglish (US)
Pages (from-to)127-133
Number of pages7
JournalCancer Letters
Issue number2
StatePublished - Apr 24 1998
Externally publishedYes


  • Cytotoxicity
  • Microtubule
  • Monoclonal antibody
  • Neutralization
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Monoclonal antibodies to taxanes that neutralize the biological activity of paclitaxel'. Together they form a unique fingerprint.

Cite this